GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neurobiological Technologies Inc (OTCPK:NTII) » Definitions » Asset Turnover

Neurobiological Technologies (Neurobiological Technologies) Asset Turnover : 0.22 (As of Sep. 2009)


View and export this data going back to 1994. Start your Free Trial

What is Neurobiological Technologies Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Neurobiological Technologies's Revenue for the three months ended in Sep. 2009 was $6.03 Mil. Neurobiological Technologies's Total Assets for the quarter that ended in Sep. 2009 was $27.22 Mil. Therefore, Neurobiological Technologies's Asset Turnover for the quarter that ended in Sep. 2009 was 0.22.

Asset Turnover is linked to ROE % through Du Pont Formula. Neurobiological Technologies's annualized ROE % for the quarter that ended in Sep. 2009 was 82.09%. It is also linked to ROA % through Du Pont Formula. Neurobiological Technologies's annualized ROA % for the quarter that ended in Sep. 2009 was 79.42%.


Neurobiological Technologies Asset Turnover Historical Data

The historical data trend for Neurobiological Technologies's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neurobiological Technologies Asset Turnover Chart

Neurobiological Technologies Annual Data
Trend Jun00 Jun01 Jun02 Jun03 Jun04 Jun05 Jun06 Jun07 Jun08 Jun09
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.20 0.76 1.06 0.55 0.78

Neurobiological Technologies Quarterly Data
Dec04 Mar05 Jun05 Sep05 Dec05 Mar06 Jun06 Sep06 Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.09 0.10 0.10 0.60 0.22

Competitive Comparison of Neurobiological Technologies's Asset Turnover

For the Biotechnology subindustry, Neurobiological Technologies's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Neurobiological Technologies's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Neurobiological Technologies's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Neurobiological Technologies's Asset Turnover falls into.



Neurobiological Technologies Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Neurobiological Technologies's Asset Turnover for the fiscal year that ended in Jun. 2009 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Jun. 2009 )/( (Total Assets (A: Jun. 2008 )+Total Assets (A: Jun. 2009 ))/ count )
=26.35/( (43.187+24.66)/ 2 )
=26.35/33.9235
=0.78

Neurobiological Technologies's Asset Turnover for the quarter that ended in Sep. 2009 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Sep. 2009 )/( (Total Assets (Q: Jun. 2009 )+Total Assets (Q: Sep. 2009 ))/ count )
=6.026/( (24.66+29.782)/ 2 )
=6.026/27.221
=0.22

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Neurobiological Technologies  (OTCPK:NTII) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Neurobiological Technologies's annulized ROE % for the quarter that ended in Sep. 2009 is

ROE %**(Q: Sep. 2009 )
=Net Income/Total Stockholders Equity
=21.62/26.336
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(21.62 / 24.104)*(24.104 / 27.221)*(27.221/ 26.336)
=Net Margin %*Asset Turnover*Equity Multiplier
=89.69 %*0.8855*1.0336
=ROA %*Equity Multiplier
=79.42 %*1.0336
=82.09 %

Note: The Net Income data used here is four times the quarterly (Sep. 2009) net income data. The Revenue data used here is four times the quarterly (Sep. 2009) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Neurobiological Technologies's annulized ROA % for the quarter that ended in Sep. 2009 is

ROA %(Q: Sep. 2009 )
=Net Income/Total Assets
=21.62/27.221
=(Net Income / Revenue)*(Revenue / Total Assets)
=(21.62 / 24.104)*(24.104 / 27.221)
=Net Margin %*Asset Turnover
=89.69 %*0.8855
=79.42 %

Note: The Net Income data used here is four times the quarterly (Sep. 2009) net income data. The Revenue data used here is four times the quarterly (Sep. 2009) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Neurobiological Technologies Asset Turnover Related Terms

Thank you for viewing the detailed overview of Neurobiological Technologies's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Neurobiological Technologies (Neurobiological Technologies) Business Description

Traded in Other Exchanges
N/A
Address
2010 Crow Canyon Place, Suite 100, San Ramon, CA, USA, 94583
Neurobiological Technologies Inc is a biopharmaceutical company historically focused on developing investigational drugs for central nervous system conditions.
Executives
Ariel Warszawski 10 percent owner C/O FIREFLY VALUE PARTNERS, LP, 551 FIFTH AVENUE, 36TH FLOOR, NEW YORK NY 10176
Ryan Heslop 10 percent owner C/O FIREFLY VALUE PARTNERS, LP, 551 FIFTH AVENUE, 36TH FLOOR, NEW YORK NY 10176
Firefly Management Co Gp, Llc 10 percent owner C/O FIREFLY VALUE PARTNERS, LP, 551 FIFTH AVENUE, 36TH FLOOR, NEW YORK NY 10176
Fvp Gp, Llc 10 percent owner C/O FIREFLY VALUE PARTNERS, LP, 551 FIFTH AVENUE, 36TH FLOOR, NEW YORK NY 10176
Firefly Value Partners, Lp 10 percent owner 426 PINEVILLE ROAD, UNIT 1, NEWTOWN PA 18940
Fvp Master Fund Lp 10 percent owner FVP GP LLC, 551 FIFTH AVENUE, 36TH FLOOR, New York NY 10176
John B Stuppin director
Abraham E Cohen director 500 SEVENTH AVE 10TH FL, C/O AXONYX INC, NEW YORK NY 10018
Abraham D Sofaer director HOOVER INSTITUTION, STANFORD UNIVERSITY, STANFORD CA 94305-6010
Biotechnology Value Fund L P other: Direct Beneficial Owner 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Partners L P/il 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Inc/il 10 percent owner 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Biotechnology Value Fund Ii Lp other: Direct Beneficial Owner 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Investments Llc other: Direct Beneficial Owner 1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104
Mark N Lampert 10 percent owner 1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104

Neurobiological Technologies (Neurobiological Technologies) Headlines